Friday, 10 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > Positive Clinical Trial Results For Gen AI-Designed Drug
Health and Wellness

Positive Clinical Trial Results For Gen AI-Designed Drug

Last updated: November 13, 2024 7:00 pm
Share
Positive Clinical Trial Results For Gen AI-Designed Drug
SHARE

InnovationRx brings you the latest updates in the world of healthcare. If you want to stay informed, make sure to subscribe to our newsletter.

Insilico Medicine recently shared the results of a clinical trial for ISM001-055, a drug designed using generative AI to target idiopathic pulmonary fibrosis. This chronic lung disease affects a significant number of Americans and can lead to difficulty in breathing as it progresses. The phase IIa trial, conducted in China, involved 71 patients who were given different doses of the drug. The results showed that the group receiving the highest dose experienced improvements in lung function and quality of life compared to the placebo group. Insilico Medicine, founded in 2014 by CEO Alex Zhavoronkov, is currently enrolling patients for a U.S.-based clinical trial.

Enveda, a Colorado-based startup, has initiated clinical trials for ENV-294, an oral inflammatory agent aimed at treating atopic dermatitis. Using AI models trained on biological data, Enveda identifies potential therapeutic compounds from natural sources and refines them into drugs. This innovative approach combines traditional medicine with modern computational biology, allowing for the discovery of novel treatments. ENV-294, derived from a plant molecule, offers a unique pathway for treating dermatitis with potentially fewer side effects. The company aims to complete its first clinical trial by the next quarter.

In other news, a study conducted in Finland and Sweden revealed that GLP-1 medications like semaglutide and liraglutide, found in drugs such as Ozempic and Wegovy, may reduce alcohol consumption and lower the risk of hospitalization for alcohol-related issues in individuals with alcohol use disorder, obesity, or Type 2 diabetes. While these findings are promising, further clinical trials are necessary to confirm the benefits of GLP-1 medications in managing alcohol addiction.

See also  July 21, verdict reached in Scopes ‘Monkey Trial’

Additionally, the healthcare industry has seen significant developments in various sectors. From FDA approvals for heart disease treatments to collaborations in drug discovery and funding rounds for companies focusing on obesity and oncology, the landscape of healthcare continues to evolve with innovative solutions and partnerships.

Stay updated with the latest healthcare news and trends by following InnovationRx. Subscribe to our newsletter for regular updates on groundbreaking research, clinical trials, and industry advancements.

TAGGED:AIDesignedclinicalDrugGenPositiveResultsTrial
Share This Article
Twitter Email Copy Link Print
Previous Article Marco Angulo, FC Cincinnati and Ecuador midfielder, dies aged 22 Marco Angulo, FC Cincinnati and Ecuador midfielder, dies aged 22
Next Article Seattle finally starts locking up shoplifters, petty criminals for first time in 4 years Seattle finally starts locking up shoplifters, petty criminals for first time in 4 years
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Trump, Vance and the attack on American universities

The Trump administration’s attack on American universities goes beyond combating antisemitism - it is a…

April 21, 2025

‘Pit Enforcer’ no more: Hellcat driver with cop costume gets probation for having gun at street takeover

A recent incident in Gage Park involving a Missouri man dressed in a police costume…

July 19, 2025

OpenAI 2024 event: How to watch new ChatGPT product reveals and demos

OpenAI is spreading holiday cheer with their "12 Days of OpenAI" series of announcements. Each…

December 20, 2024

Inside the fall of Vinay Prasad, the FDA’s top vaccine official

Vinay Prasad, an official at the Food and Drug Administration, found himself facing a series…

July 30, 2025

Iran’s Nuclear Deception: The World Must Stop Playing Along |

Photo Courtesy of the Jerusalem Institute for Strategy and Security This story originally was published…

August 10, 2025

You Might Also Like

STAT+: HHS employees to be fired as White House enacts mass terminations it blames on shutdown
Health and Wellness

STAT+: HHS employees to be fired as White House enacts mass terminations it blames on shutdown

October 10, 2025
No, circumcision doesn’t cause autism
Health and Wellness

No, circumcision doesn’t cause autism

October 10, 2025
Jay Shetty and his health advice are everywhere. It’s by design
Health and Wellness

Jay Shetty and his health advice are everywhere. It’s by design

October 10, 2025
Cancer drug maker takes sudden pivot into crypto
Economy

Cancer drug maker takes sudden pivot into crypto

October 9, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?